MCID: GLL022
MIFTS: 60

Guillain-Barre Syndrome

Categories: Rare diseases, Neuronal diseases, Immune diseases, Genetic diseases

Aliases & Classifications for Guillain-Barre Syndrome

MalaCards integrated aliases for Guillain-Barre Syndrome:

Name: Guillain-Barre Syndrome 12 53 25 37 55 43 44 15 73 53 25 54
Fisher Syndrome 25 54 37
Acute Inflammatory Demyelinating Polyneuropathy 53 73
Acute Inflammatory Polyneuropathy 53 25
Gbs 53 25
Acute Inflammatory Demyelinating Polyradiculoneuropathy 53
Acute Autoimmune Peripheral Neuropathy 53
Landry-Guillain-Barre-Strohl Syndrome 53
Acute Immune-Mediated Polyneuropathy 53
Acute Postinfectious Polyneuropathy 12
Guillain-Barré-Strohl Syndrome 53
Landry-Guillain-Barre Syndrome 25
Acute Inflammatory Neuropathy 53
Acute Infectious Polyneuritis 25
Acute Infective Polyneuritis 12
Post-Infectious Polyneuritis 12
Landry's Ascending Paralysis 53
Postinfectious Polyneuritis 12
Post-Infective Polyneuritis 53
Miller Fisher Syndrome 73
Infectious Neuronitis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12842
ICD10 33 G61.0
MeSH 44 D020275
NCIt 50 C116345

Summaries for Guillain-Barre Syndrome

MedlinePlus : 43 Guillain-Barre syndrome is a rare disorder that causes your immune system to attack your peripheral nervous system (PNS). The PNS nerves connect your brain and spinal cord with the rest of your body. Damage to these nerves makes it hard for them to transmit signals. As a result, your muscles have trouble responding to your brain. No one knows what causes the syndrome. Sometimes it is triggered by an infection, surgery, or a vaccination. The first symptom is usually weakness or a tingling feeling in your legs. The feeling can spread to your upper body. In severe cases, you become almost paralyzed. This is life-threatening. You might need a respirator to breathe. Symptoms usually worsen over a period of weeks and then stabilize. Guillain-Barre can be hard to diagnose. Possible tests include nerve tests and a spinal tap. Most people recover. Recovery can take a few weeks to a few years. Treatment can help symptoms, and may include medicines or a procedure called plasma exchange. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Guillain-Barre Syndrome, also known as fisher syndrome, is related to miller fisher syndrome and peripheral nervous system disease, and has symptoms including back pain, headache and neuralgia. An important gene associated with Guillain-Barre Syndrome is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are Development Angiotensin activation of ERK and Allograft rejection. The drugs Vaccines and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and spinal cord, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An autoimmune disease of peripheral nervous system that causes body's immune system to attack part of the peripheral nervous system.

NIH Rare Diseases : 53 Guillain-Barré syndrome (GBS) is a rare syndrome in which the body’s immune system attacks part of the peripheral nervous system. The peripheral nervous system carries signals from the brain to the muscles. Symptoms of GBS include muscle weakness, numbness, and tingling sensations, which can increase in intensity until the muscles cannot be used at all (paralysis). The exact cause of Guillain-Barré syndrome is unknown. In most cases, GBS occurs a few days or weeks after symptoms of a viral infection. In rare cases, GBS may run in families. A diagnosis of GBS is suspected when a person has symptoms suggestive of the syndrome. A variety of tests, including a spinal tap, may be completed to confirm the diagnosis. Treatment options may include plasma exchange (plasmapheresis) and immunoglobulin therapy. 

NINDS : 54 Miller Fisher syndrome is a rare, acquired nerve disease that is considered to be a variant of Guillain-Barré syndrome. It is characterized by abnormal muscle coordination, paralysis of the eye muscles, and absence of the tendon reflexes. Like Guillain-Barré syndrome, symptoms may be preceded by a viral illness. Additional symptoms include generalized muscle weakness and respiratory failure. The majority of individuals with Miller Fisher syndrome have a unique antibody that characterizes the disorder.

Wikipedia : 76 Guillain–Barré syndrome (GBS) is a rapid-onset muscle weakness caused by the immune system damaging the... more...

Related Diseases for Guillain-Barre Syndrome

Diseases in the Guillain-Barre Syndrome family:

Guillain-Barre Syndrome, Familial

Diseases related to Guillain-Barre Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 290)
# Related Disease Score Top Affiliating Genes
1 miller fisher syndrome 33.3 CD40LG TNF
2 peripheral nervous system disease 31.7 CD40LG MPZ PMP22
3 burns 30.8 ALB TNF
4 chronic inflammatory demyelinating polyradiculoneuropathy 30.7 ALB MPZ PMP22
5 demyelinating polyneuropathy 30.6 ALB HP PMP22
6 membranous nephropathy 30.6 ALB CD79A TNF
7 hepatitis e 30.2 ALB CD40LG TNF
8 purpura 29.9 CD40LG CD79A TNF
9 polyneuropathy 29.7 CD40LG MBP MPZ PMP22
10 hemorrhagic fever 29.7 ALB CD40LG TNF
11 hemorrhagic fever with renal syndrome 29.7 ALB CD40LG TNF
12 polyradiculoneuropathy 29.4 ALB MBP MPZ PMP2 PMP22
13 glomerulonephritis 29.3 ALB CD40LG CD79A
14 meningoencephalitis 29.2 ALB CD40LG CD79A MBP
15 multiple sclerosis 29.1 HLA-DQB1 MBP MPZ TNF TNFRSF1A
16 systemic lupus erythematosus 28.1 ALB CD40LG CD79A HLA-DQB1 TNF TNFRSF1B
17 celiac disease 1 27.7 ALB CD40LG CD79A HLA-DQB1 HP TNF
18 guillain-barre syndrome, familial 12.6
19 pharyngeal-cervical-brachial variant of guillain-barré syndrome 12.3
20 paraparetic variant of guillain-barré syndrome 12.3
21 chronic inflammatory demyelinating polyneuropathy 11.6
22 autonomic dysfunction 11.5
23 dysautonomia 11.5
24 neuropathy, hereditary sensory and autonomic, type iii 11.2
25 acute flaccid myelitis 11.2
26 zika virus infection 11.2
27 hereditary neuropathy with liability to pressure palsy 11.0 MPZ PMP22
28 charcot-marie-tooth neuropathy type 1 10.9 MPZ PMP22
29 foot drop 10.9 MPZ PMP22
30 roussy-levy hereditary areflexic dystasia 10.9 MPZ PMP22
31 charcot-marie-tooth disease, demyelinating, type 1f 10.9 MPZ PMP22
32 charcot-marie-tooth disease, demyelinating, type 1c 10.9 MPZ PMP22
33 ostertagiasis 10.9 ALB CD79A
34 dermatitis, atopic, 3 10.9 ALB CD79A
35 skin sarcoidosis 10.8 TNF TNFRSF1B
36 scleral disease 10.8 TNF TNFRSF1B
37 farmer's lung 10.8 CD79A TNF
38 pustulosis of palm and sole 10.8 TNF TNFRSF1B
39 congenital hypomyelination neuropathy 10.7 MBP MPZ PMP22
40 root caries 10.7 ALB CD79A
41 hereditary neuropathies 10.7 MBP MPZ PMP22
42 beryllium disease 10.7 HLA-DQB1 TNF
43 pelizaeus-merzbacher disease 10.7 MBP MPZ PMP22
44 optic neuritis 10.7 MBP MPZ TNF
45 peroneal neuropathy 10.7 TNF TNFRSF1B
46 autoimmune pancreatitis 10.7 HLA-DQB1 TNF
47 chronic beryllium disease 10.7 HLA-DQB1 TNF
48 protein-energy malnutrition 10.6 ALB CD79A TNF
49 keratoconjunctivitis sicca 10.6 ALB CD79A TNF
50 parotitis 10.6 ALB CD79A

Graphical network of the top 20 diseases related to Guillain-Barre Syndrome:



Diseases related to Guillain-Barre Syndrome

Symptoms & Phenotypes for Guillain-Barre Syndrome

UMLS symptoms related to Guillain-Barre Syndrome:


back pain, headache, neuralgia, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, sleeplessness, cerebellar ataxia, ophthalmoplegia

GenomeRNAi Phenotypes related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00381-A-1 9.28 CD79A HLA-DQB1 MPZ
2 Decreased viability GR00381-A-3 9.28 MPZ CD79A HLA-DQB1
3 Decreased viability GR00402-S-2 9.28 CD79A HLA-DQB1 MPZ

MGI Mouse Phenotypes related to Guillain-Barre Syndrome:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.25 MPZ PMP2 PMP22 TNF TNFRSF1A TNFRSF1B
2 cellular MP:0005384 10.2 ALB CD40LG CD79A HLA-DQB1 HP MBP
3 behavior/neurological MP:0005386 10.15 HCRT HLA-DQB1 MBP MPZ PMP2 PMP22
4 hematopoietic system MP:0005397 10.09 HP MBP MPZ TNF TNFRSF1A TNFRSF1B
5 cardiovascular system MP:0005385 10.08 TNF TNFRSF1A TNFRSF1B CD40LG DAAM2 HCRT
6 immune system MP:0005387 10.02 CD40LG CD79A HLA-DQB1 HP MBP MPZ
7 liver/biliary system MP:0005370 9.87 TNFRSF1A TNFRSF1B ALB CD79A HLA-DQB1 HP
8 muscle MP:0005369 9.86 ALB DAAM2 HCRT HLA-DQB1 PMP22 TNF
9 nervous system MP:0003631 9.7 CD40LG CD79A HCRT HLA-DQB1 MBP MPZ
10 neoplasm MP:0002006 9.63 ALB CD79A HP TNF TNFRSF1A TNFRSF1B
11 renal/urinary system MP:0005367 9.17 ALB CD40LG CD79A HLA-DQB1 HP TNFRSF1A

Drugs & Therapeutics for Guillain-Barre Syndrome

Drugs for Guillain-Barre Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 37)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Vaccines Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
2 Antibodies Phase 3,Phase 2,Not Applicable
3 Immunoglobulins Phase 3,Phase 2,Not Applicable
4
4-Aminopyridine Approved Phase 2 504-24-5 1727
5
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
6
Lactitol Investigational Phase 2 585-86-4 3871
7 Complement System Proteins Phase 2
8 gamma-Globulins Phase 2,Not Applicable
9 Immunoglobulins, Intravenous Phase 2,Not Applicable
10 Pharmaceutical Solutions Phase 2
11 Rho(D) Immune Globulin Phase 2,Not Applicable
12 Potassium Channel Blockers Phase 2
13 MF59 oil emulsion Phase 2
14 Anti-Inflammatory Agents Phase 2
15 Antineoplastic Agents, Hormonal Phase 2
16 glucocorticoids Phase 2
17 Hormone Antagonists Phase 2
18 Hormones Phase 2
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
20 Hemagglutinins Phase 2
21 Chorionic Gonadotropin Phase 2
22
Infliximab Approved 170277-31-3
23
nivolumab Approved 946414-94-4
24
Thiamine Approved, Investigational, Nutraceutical, Vet_approved 59-43-8, 70-16-6 1130
25
Citric Acid Approved, Nutraceutical, Vet_approved Not Applicable 77-92-9 311
26 Vitamin B Complex
27 Vitamins
28 Anticoagulants Not Applicable
29 Calcium, Dietary Not Applicable
30 Chelating Agents Not Applicable
31 Antirheumatic Agents
32 Dermatologic Agents
33 Gastrointestinal Agents
34 Autoantibodies
35 Immunoglobulin G
36 Thiamin Nutraceutical
37 Citrate Nutraceutical Not Applicable

Interventional clinical trials:

(show top 50) (show all 57)
# Name Status NCT ID Phase Drugs
1 A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults Completed NCT01427309 Phase 4
2 Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination Unknown status NCT01777308 Phase 3
3 Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome Completed NCT02342184 Phase 3 GB-0998
4 Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome Completed NCT02221271 Phase 3 NPB-01
5 Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801 Completed NCT01604746 Phase 3
6 A Study To Evaluate A Booster Dose Of Menacwy-tt Vaccine Administered 10 Years After Healthy Subjects Aged 11-17 Years Received Either Menacwy-tt Vaccine (Nimenrix(Registered)) Or Mencevax Acwy(Registered). Recruiting NCT03189745 Phase 3
7 Study to Evaluate the Long-term Antibody Persistence of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine (GSK134612) Versus Mencevax ACWY in Healthy Adolescents and Adults and Booster Response to MenACWY-TT Vaccine Administered at 10 Years Post-prima Active, not recruiting NCT01934140 Phase 3
8 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Not yet recruiting NCT03486873 Phase 3 Standard of Care (SOC)
9 Multi-Year Study of Fluzone High-Dose Influenza Vaccine Compared With Fluzone® Vaccine in Adults Aged 65 Years and Older Terminated NCT00976027 Phase 3
10 Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study Unknown status NCT02029378 Phase 2 Eculizumab
11 Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome (GBS) Patients Completed NCT02780570 Phase 2
12 Early Mechanical Ventilation for Guillain Barré Syndrome Completed NCT00167622 Phase 2
13 Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine Completed NCT00056810 Phase 2 4-aminopyridine (4-AP)
14 JET-GBS - Japanese Eculizumab Trial for GBS Completed NCT02493725 Phase 2 Eculizumab;Placebo
15 Seasonal Flu Vaccine in Adult Transplant Recipients Completed NCT01258023 Phase 2
16 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
17 Sanofi H1N1 + TIV - Adults and Elderly Completed NCT00943878 Phase 2 Placebo
18 Novartis H1N1 Vaccine in Pregnant Women Completed NCT00992719 Phase 2
19 2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women Completed NCT01173211 Phase 2
20 Sanofi H1N1 Influenza Vaccine Administered at Different Dose Levels With and Without AS03 Adjuvant in Healthy Adult and Elderly Populations Completed NCT00963157 Phase 2 AS03
21 H1N1 Vaccine at Two Dose Levels in HIV Positive Adults Completed NCT00992433 Phase 2
22 Sanofi Pasteur, TIV + H1N1, Pediatric Population Completed NCT00943202 Phase 2
23 H1N1 Vaccine in Pregnant Women Completed NCT00963430 Phase 2
24 Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure Recruiting NCT03174964 Phase 2 IVIg
25 Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss Recruiting NCT03174951 Phase 2 IVIg
26 Study of GLS-5700 in Dengue Virus Seropositive Adults Active, not recruiting NCT02887482 Phase 1
27 Study of GLS-5700 in Healthy Volunteers Active, not recruiting NCT02809443 Phase 1
28 sCD163 as a Potential Biomarker in Guillain- Barré Syndrome Unknown status NCT02582853
29 The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation Unknown status NCT00173199
30 Change of Nerve Conduction Properties in IVIg Dependent Neuropathies Unknown status NCT01655394
31 Detection of Peripheral Blood Biomarkers in Intermediate Phase Spinal Cord Injury: Correlation With Neurological and Functional Outcomes, and Comparison to Other Central and Peripheral Neurological Conditions. Unknown status NCT01516385
32 Thiamin (Vitamin B1) Levels in Eating Disorder Adolescent Patients Unknown status NCT02164487
33 Perception and Multisensory Integration in Neurological Patients Using fMRI Unknown status NCT01469858 Not Applicable
34 Intravenous Immunoglobulin (IVIG) Versus Plasma Exchange (PE) for Ventilated Children With Guillain Barre Syndrome (GBS) Completed NCT01306578 Not Applicable IVIG
35 Safety Study of GBS Following Menactra Meningococcal Vaccination Completed NCT00575653
36 Effects of Robotic-assisted Gait Training In Non-Ambulatory Patients After Guillain-Barré Syndrome Completed NCT02883270 Not Applicable
37 Prospective Study on Swallowing/Breathing Interactions in Severe Guillain Barre Syndrome. Completed NCT01024088
38 Brain Computer Interface for Communication in ICU: a Feasibility Study Completed NCT01005524
39 Regional Citrate Anticoagulation in Plasma Exchange Treatment Completed NCT01370200 Not Applicable
40 Cervarix Long-term Safety Surveillance Completed NCT01498627
41 Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom Completed NCT01953822
42 Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age Completed NCT01985997
43 Surveillance for Adverse Events Following Pandemic H1N1 Immunization Completed NCT01289418
44 Surveillance for Adverse Events Following Influenza Immunization Completed NCT01318876
45 Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines Completed NCT02893878
46 Database Surveillance Safety Study of PENTACEL® Vaccine Completed NCT00804284
47 Recovery of Visual Acuity in People With Vestibular Deficits Completed NCT00411216 Not Applicable
48 Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035) Completed NCT00705614
49 International Guillain-Barré Syndrome Outcome Study Recruiting NCT01582763
50 Neurologic Manifestations of the Arbovirus Infection in Colombia Recruiting NCT03206541

Search NIH Clinical Center for Guillain-Barre Syndrome

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: guillain-barre syndrome

Genetic Tests for Guillain-Barre Syndrome

Anatomical Context for Guillain-Barre Syndrome

MalaCards organs/tissues related to Guillain-Barre Syndrome:

41
Testes, Brain, Spinal Cord, Eye, Heart, Skin, T Cells

Publications for Guillain-Barre Syndrome

Articles related to Guillain-Barre Syndrome:

(show top 50) (show all 201)
# Title Authors Year
1
Case report: Guillain-Barre syndrome with pneumococcus - A new association in pediatrics. ( 29387550 )
2018
2
Post Vaccination Guillain Barre Syndrome: A Case Report. ( 29930889 )
2018
3
Motor Nerve Conduction Block Predicting Outcome of Guillain-Barre Syndrome. ( 29910770 )
2018
4
Epidemiology and Clinical Features of Guillain-Barre Syndrome in Isfahan, Iran. ( 29930927 )
2018
5
Guillain-Barre syndrome associated with hemorrhagic fever with renal syndrome in China: a case report. ( 29587642 )
2018
6
Characteristics, incidence and outcome of patients admitted to intensive care unit with Guillain-Barre syndrome in Australia and New Zealand. ( 29413724 )
2018
7
Guillain-Barre syndrome caused by hepatitis E infection: case report and literature review. ( 29357816 )
2018
8
Acute-onset Restless legs syndrome in acute neurological conditions-a prospective study on patients with the Guillain-Barre syndrome and acute stroke. ( 29359321 )
2018
9
Nivolumab-Associated Guillain-Barre Syndrome in a Patient With Non-Small-Cell Lung Cancer. ( 29889678 )
2018
10
Acute Fulminant Uremic Neuropathy Following Coronary Angiography Mimicking Guillain-Barre Syndrome. ( 28706599 )
2017
11
Value of protein concentration in cerebrospinal fluid in paediatric patients with Guillain-Barre syndrome. ( 28870420 )
2017
12
Familial amyloid cardiomyopathy masquerading as chronic Guillain-Barre syndrome: things are not always what they seem. ( 28425041 )
2017
13
Long-term complete remission in a patient with focal segmental glomerulosclerosis associated with Guillain-Barre syndrome. ( 28921751 )
2017
14
Bilateral Ptosis due to Sympathetic Dysfunction as a Feature of Guillain-Barre Syndrome. ( 28827488 )
2017
15
Clinical association: Lyme disease and Guillain-Barre syndrome. ( 28711274 )
2017
16
Early electrophysiological findings in acute inflammatory demyelinating polyradiculoneuropathy variant of Guillain-Barre syndrome in the Pakistani populationA -A a comparison with global data. ( 29091318 )
2017
17
Reversible Splenial Lesion Syndrome After Intravenous Immunoglobulin Treatment for Guillain-Barre Syndrome. ( 28816832 )
2017
18
Zika virus-induced neurological critical illness in Latin America: Severe Guillain-Barre Syndrome and encephalitis. ( 28806562 )
2017
19
Disturbance of Plasma Lipid Metabolic Profile in Guillain-Barre Syndrome. ( 28811529 )
2017
20
Anesthesia for cesarean section in parturient with Guillain Barre Syndrome: a case report. ( 29878296 )
2017
21
Guillain-Barre Syndrome with Falciparum Malaria and Scrub Typhus Mixed Infection-An Unusual Combination. ( 29207762 )
2017
22
Guillain Barre Syndrome in the elderly: Experience from a tertiary-care hospital in India. ( 28890042 )
2017
23
Ventilator-Associated Pneumonia (VAP) in a Patient with Guillain-Barre Syndrome. ( 28790230 )
2017
24
Guillain-Barre Syndrome Induced by Heat Stroke: a Case Report and Literature Review. ( 28879705 )
2017
25
Poster 353 Acute Onset Chronic Inflammatory Demyelinating Polyneuropathy (A-CIDP) with CNS Involvement Initially Diagnosed as Guillain-Barre Syndrome (GBS): A Case Report. ( 27673107 )
2016
26
The pathogenesis of demyelinating form of Guillain-Barre syndrome: proteo-peptidomic and immunological profiling of physiological fluids. ( 27143409 )
2016
27
Author response: Successful treatment of Guillain-Barre syndrome by Ayurvedic treatment. ( 27621525 )
2016
28
Vision Loss in Guillain-Barre Syndrome: Is it a Complication of Guillain-Barre Syndrome or Just a Coincidence? ( 27621799 )
2016
29
Concurrency of Guillain-Barre syndrome and acute transverse myelitis: a case report and review of literature. ( 28018472 )
2016
30
Poster 344 Upper Extremity Weakness Due to Bilateral Brachial Plexopathy from Guillain-Barre Syndrome in a Cancer Patient: A Case Report. ( 27673098 )
2016
31
Successful treatment of Guillain-Barre syndrome by Ayurvedic treatment. ( 27143805 )
2016
32
Concomitant Guillain Barre Syndrome and Transverse Myelitis as Initial Neuropsychiatric Manifestation in a Case of Lupus: A Diagnostic Quandary. ( 27242943 )
2016
33
Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis and Guillain-Barre Syndrome in a 16-Month-Old Child. ( 28503601 )
2016
34
Reducing the economic burden in management of Guillain-Barre syndrome using modified plasmapheresis. ( 27605847 )
2016
35
Bilateral Ptosis as the First Presentation of Guillain-Barre Syndrome. ( 27057192 )
2016
36
Electrophysiological observations in critically ill Guillain-Barre syndrome. ( 27625229 )
2016
37
Carcinoid Tumor-Associated Paraneoplastic Polyneuropathy that Mimics Guillain-Barre Syndrome. ( 28360817 )
2016
38
Facial Diplegia with Paresthesia: An Uncommon Variant of Guillain-Barre Syndrome. ( 27630886 )
2016
39
Prevalence of Autonomic Dysfunction in Hospitalized Patients with Guillain- Barre Syndrome. ( 28039863 )
2016
40
An Overlapping Case of Miller Fisher Syndrome, Bickerstaff's Encephalitis, and the ASMAN Variant of Guillain-Barre Syndrome. ( 27974981 )
2016
41
Co-Cccurrence of Guillain-Barre Syndrome and Primary SjAPgren Syndrome in an Elderly Woman. ( 27854085 )
2016
42
Guillaine-barre syndrome; a rare complication of melioidosis. a case report. ( 27506202 )
2016
43
Correlation Between Daam2 Expression Changes and Demyelination in Guillain-Barre Syndrome. ( 26293489 )
2016
44
Guillain-Barre syndrome in acute lymphoblastic leukemia: Causal or coincidental. ( 25878750 )
2015
45
Acute toxic neuropathy mimicking guillain barre syndrome. ( 25811007 )
2015
46
Similarities of serum anti-ganglioside antibodies in first and third episodes of recurrent Guillain-Barre syndrome: case report. ( 25845761 )
2015
47
Guillain - Barre syndrome in a patient with acute myocardial infarction with ventricular septal defect repair treated with plasma exchange. ( 25722582 )
2015
48
Outcome of Guillain-Barre syndrome patients with respiratory paralysis. ( 26475599 )
2015
49
Guillain-Barre Syndrome: Clinical Presentation, Treatment Pattern And Outcome. ( 26533694 )
2015
50
A Case of Visceral Autonomic Neuropathy Complicated by Guillain-Barre Syndrome Accompanied with Cyclic Vomiting Syndrome-like Disorder in a Child. ( 26157699 )
2015

Variations for Guillain-Barre Syndrome

Expression for Guillain-Barre Syndrome

Search GEO for disease gene expression data for Guillain-Barre Syndrome.

Pathways for Guillain-Barre Syndrome

Pathways related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.74 CD40LG CD79A TNF TNFRSF1A TNFRSF1B
2
Show member pathways
12.67 CD40LG HLA-DQB1 TNF TNFRSF1A TNFRSF1B
3
Show member pathways
12.47 CD40LG TNF TNFRSF1A TNFRSF1B
4
Show member pathways
12.15 CD40LG TNF TNFRSF1A TNFRSF1B
5 12.07 CD40LG CD79A TNF TNFRSF1A TNFRSF1B
6
Show member pathways
12.03 CD40LG HLA-DQB1 TNF TNFRSF1A
7 12 CD40LG TNF TNFRSF1A TNFRSF1B
8
Show member pathways
11.8 TNF TNFRSF1A TNFRSF1B
9 11.77 TNF TNFRSF1A TNFRSF1B
10 11.73 MBP MPZ PMP22
11 11.68 CD40LG TNF TNFRSF1A
12 11.53 TNF TNFRSF1A TNFRSF1B
13
Show member pathways
11.47 CD40LG TNF TNFRSF1A
14 11.39 TNF TNFRSF1A TNFRSF1B
15
Show member pathways
11.28 TNF TNFRSF1A TNFRSF1B
16 11.23 TNF TNFRSF1A TNFRSF1B
17 10.95 CD40LG TNFRSF1A TNFRSF1B
18
Show member pathways
10.79 CD40LG TNF TNFRSF1A TNFRSF1B
19 10.64 TNF TNFRSF1A TNFRSF1B

GO Terms for Guillain-Barre Syndrome

Cellular components related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane raft GO:0045121 9.46 CD79A TNF TNFRSF1A TNFRSF1B
2 compact myelin GO:0043218 8.96 MBP PMP22
3 myelin sheath GO:0043209 8.92 ALB MBP MPZ PMP2

Biological processes related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.78 HCRT MBP MPZ PMP22
2 apoptotic signaling pathway GO:0097190 9.63 TNF TNFRSF1A TNFRSF1B
3 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.49 TNF TNFRSF1B
4 positive regulation of ceramide biosynthetic process GO:2000304 9.43 TNF TNFRSF1A
5 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.43 TNF TNFRSF1A TNFRSF1B
6 death-inducing signaling complex assembly GO:0071550 9.4 TNF TNFRSF1A
7 regulation of establishment of endothelial barrier GO:1903140 9.37 TNF TNFRSF1A
8 myelination GO:0042552 9.33 MBP MPZ PMP22
9 regulation of immunoglobulin secretion GO:0051023 9.32 CD40LG TNF
10 tumor necrosis factor-mediated signaling pathway GO:0033209 9.26 CD40LG TNF TNFRSF1A TNFRSF1B
11 immune response GO:0006955 9.1 CD40LG HLA-DQB1 MBP TNF TNFRSF1A TNFRSF1B

Molecular functions related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fatty acid binding GO:0005504 8.62 ALB PMP2

Sources for Guillain-Barre Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....